公开(公告)号：EP0910360A1

公开(公告)日：1999-04-28

申请号：EP97928368.0

申请日：1997-06-24

申请人： NYCOMED IMAGING AS

发明人： TOWART, Robertson ,  KARLSSON, Jan, Olof, Gustav ,  JYNGE, Per

IPC分类号： A61K45 ,  A61K31 ,  A61K33 ,  A61P39

CPC分类号： A61K33/32 ,  A61K31/198 ,  A61K31/28 ,  A61K31/4415 ,  A61K31/444 ,  A61K31/675 ,  Y10S514/836 ,  A61K2300/00

摘要： The invention relates to the use of certain chelating agents and their metal chelates and to the use of certain manganese containing compounds, in particular manganese chelates, in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an antitumor agent. Such compounds are particularly effective in reducing the side-effects of anthracycline drugs and/or paclitaxel.

公开(公告)号：EP1060174A1

公开(公告)日：2000-12-20

申请号：EP98962567.8

申请日：1998-12-18

申请人： NYCOMED IMAGING AS

发明人： TOWART, Robertson ,  KARLSSON, Jan, Olof, Gustav ,  WISTRAND, Lars, Göran ,  MALMGREN, H kan

IPC分类号： C07D401/12 ,  A61K31/44

CPC分类号： C07D213/65

摘要： Chelating agents, in particular dipyridoxyl and aminopolycarboxylic acid based chelating agents, and their metal chelates, when linked directly or indirectly to at least one nitric oxide releasing moiety, or when use in combination with nitric oxide or a nitric oxide releasing moiety have been found to be effective in treating a variety of disorders. In particular, such compounds may be used in treating conditions associated with the presence of free radicals in the body, e.g. reperfusion injuries, and in reducing the cardiotoxicity of anti-tumor agents, e.g. anthracyclines and/or paclitaxel.

公开(公告)号：EP1054670A2

公开(公告)日：2000-11-29

申请号：EP98962566.0

申请日：1998-12-18

申请人： NYCOMED IMAGING AS

发明人： KARLSSON, Jan, Olof, Gustav ,  ANDERSSON, Rolf, Göran, Gustav ,  OLSSON, Anders ,  ZIEDEN, Bo ,  JYNGE, Per ,  GRIFFITH, Tudor ,  GRANT, Derek ,  TOWART, Robertson ,  REFSUM, Helge

IPC分类号： A61K31/44

CPC分类号： A61K31/444 ,  A61K31/198 ,  A61K31/675 ,  Y02A50/411 ,  Y02A50/414 ,  Y10S514/824

摘要： The invention provides the use of dipyridoxyl or aminopolycarboxylic acid based chelating agents, metal chelates and salts thereof, in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of atherosclerosis and related conditions in the human or non-human animal body. Preferred compounds for use in the method of the invention are compounds of formula (I) or a metal chelate or salt thereof (wherein in formula (I) each R1 independently represents hydrogen or -CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; each R2 independently represents a group XYR6; X represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by a group R7; Y represents a bond, an oxygen atom or a group NR6; R6 is a hydrogen atom, a group COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from COOR8, CONR82, NR82, OR8, =R8, =O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation, e.g. an alkali or alkaline earth cation, an ammonium ion or an organic amine cation, such as a meglumine ion; R3 represents a C1-8 alkylene group, preferably a C1-6, e.g. a C2-4 alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; each R4 independently represents hydrogen or C1-3 alkyl; and each R9 independently may be absent or represents hydrogen, alkyl, hydroxyalkyl or carboxyalkyl).

公开(公告)号：EP0936915A1

公开(公告)日：1999-08-25

申请号：EP97928369.0

申请日：1997-06-24

申请人： NYCOMED IMAGING AS

发明人： KARLSSON, Jan, Olof, Gustav ,  JYNGE, Per ,  TOWART, Robertson

IPC分类号： A61K45 ,  A61K31 ,  A61K33 ,  A61P39

CPC分类号： A61K33/32 ,  A61K31/198 ,  A61K31/28 ,  A61K31/4415 ,  A61K31/444 ,  A61K31/675 ,  Y10S514/836 ,  A61K2300/00

摘要： The invention provides the use of a compound of formula (I) or a metal chelate or salt thereof in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of conditions resulting from the presence of free radicals in the human or non-human animal body (wherein in formula (I): each R1 independently represents hydrogen or -CH¿2?COR?5; R5¿ represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; each R2 independently represents a group XYR6; X represents a bond, or a C¿1-3? alkylene or oxoalkylene group optionally substituted by a group R?7¿; Y represents a bond, an oxygen atom or a group NR6; R6 is a hydrogen atom, a group COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from COOR?8, CONR8¿2, NR82, OR8, =NR8, =O, OP(O) (OR8)R7 and OSO¿3M; R?7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents a C¿1-8? alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and each R?4¿ independently represents hydrogen or C¿1-3? alkyl). Such compounds are particularly effective in relieving symptoms associated with reperfusion of ischemic tissue and in treating or preventing radiation-induced injury.